阿瑞匹坦预防放化疗所致恶心呕吐新进展

Chemotherapy-associated nausea and vomiting (CINV) is the most common adverse reaction of chemotherapy for malignant tumors. Nobel Prize winner Albert Schweitzer once said in his autobiography "Reverence for Life" that "pain is more terrifying than death itself." Nausea and vomiting are the most frightening experiences for cancer patients. They are also the main reasons that affect the quality of life and treatment compliance of subjects and increase the use of medical resources. It is the first NK-1 receptor antagonist that can penetrate the body's brain barrier and inhibit the vomiting effect of substance P. Its affinity and selectivity are better than those of 5-HT receptor antagonists. Therefore, the combination of 5-HT receptor antagonists, aprepitant, and dexamethasone has a stronger effect on preventing and alleviating nausea and vomiting during chemotherapy.

One study included 52 patients in the highly emetogenic chemotherapy group. 83% of the patients had clinical stage IV tumors. They received a triple antiemetic regimen of 15 mg oral mirtazapine combined with aprepitant and palonosetron. The effective control rates of nausea and vomiting reached 75% and 90% respectively. .4%, which is not only no lower than the combined antiemetic regimen containing olanzapine recommended by the guidelines, but also has an antiemetic effect comparable to the triple CINV prevention regimen (NK-1 receptor antagonist combined with 5-HT3 receptor antagonist and dexamethasone) recommended by authoritative guidelines.

What was found in the experiment were: pelvic pain, bradycardia, hiccups, elevated liver index ALT, anorexia, disorientation, duodenal ulcer perforation, upper respiratory tract infection, tachycardia, constipation, headache, skeletal pain, rash, hypokalemia, redness, fatigue, weakness, pain, anxiety, weakness, Stevens-Johnson syndrome, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.